— How clinically meaningful the impact of randomized trial findings is debatable
May 18, 2026
• 3 min read
As the locking fluid for central venous access device (CVAD) ports in the ICU, an investigational 4% solution of tetrasodium EDTA reduced complications compared with a standard fluid, a randomized trial showed.
Combined risk of CVAD-associated bloodstream infection, catheter occlusion requiring thrombolysis, or catheter removal due to occlusion came out 32% lower with the EDTA locking fluid versus a control of saline or 4% citrate (13.1 vs 19.9 events per 1,000 catheter days, rate ratio 0.68, 95% CI 0.47-0.96, P=0.03).
